Vanda Pharmaceuticals | VNDA - Selling And Administration Expenses


Vanda Pharmaceuticals reported $39.28M in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 41.74M 4.28M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Esperion Therapeutics USD 39.42M 456K Dec/2025
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 247.26M 34.78M Mar/2026
J&J USD 6.03B 719M Mar/2026
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Ligand Pharmaceuticals USD 20.84M 4.19M Mar/2026
Merck USD 2.67B 180M Mar/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 173M 135M Mar/2026
Novartis USD 3.44B 132M Dec/2025
Pfizer USD 2.92B 1.16B Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.33B 419M Mar/2026
Takeda JPY 292B 9.21B Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Veracyte USD 50.84M 7.53M Mar/2026